New Attana publication - Increased target specificity for new drugs by applying Attana´s technology to understand and optimize multivalent drug interactions
Attana’s technology was extensively used in a new paper published in Biosensors and Bioelectronics. The paper is a result of a collaboration project, which originates from the EU-project Dynano, between University of Namur, KTH - Royal Institute of Technology, University of Massachusetts Lowell, Linnaeus University and Attana. In the paper it is demonstrated that the Attana technology is an excellent tool to characterize and distinguish between different kinds of interactions, which are important for the development of new drugs with improved specificity.
In the publication it is shown that Attana's QCM-technology is an excellent tool to study multiple interactions. In particular, the Attana technology can be used to outline multivalency effects in carbohydrate-lectin interactions. This can be used to create well-defined, precisely glycosylated nanoplatforms of various symmetry, charge and size that has the opportunity to become important tools to probe the “cluster glycoside effect”. This, amongst others things, can be of importance to specifically target bacteria for the design of next generation antibiotics, which aim at eliminatic antibiotics resistance.
Within the the Dynano network, Attana has been actively working in order to develop assays suitable for bacterial and carbohydrate assays. This has resulted in several important publications:
- Improved recongnition of bacteria for next generation antibiotics
- Bacterial surface glycans for glycophenotyping
- Determination of glycosignature of bacteria
- Sterical influence on specificity and affinity
- Affinity analysis of specific carobohydrate interactions
In addition, related work has been published by other groups using the Attana technology:
- Functionalized carbohydrate surface for improved understanding of carbohydrate interactions
- Glycopolymere nanoparticles for targeted carbohydrate interactions
To learn more on published scientific papers enabled by Attana, please see our full publication list
For more information, please contact:
Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com.
Tags:
